Wendy Yeh

Dr. Yeh is an experienced physician-scientist and drug developer who has been responsible for the successful clinical development and registration of multiple transformative medicines.  She brings 20+ years of experience in research and clinical development in infectious diseases and immunology, and currently oversees the clinical development pipeline for the Respiratory portfolio at Vir.  Prior to Vir, she held multiple positions of increasing responsibility at Merck Research Laboratories and Principia Biopharma.  She has been responsible for the successful clinical development, registration, and lifecycle management of multiple transformative medicines, such as grazoprevir/elbasvir (Zepatier®) for treatment of HCV, letermovir (PrevymisTM) for prevention of CMV in immunocompromised hosts, and sotrovimab (Xevudy) for treatment of SARS-CoV2.

 Dr. Yeh earned her B.S. from Stanford University, M.D. from University of Washington, and completed her clinical training in Internal Medicine and Infectious Diseases at Brigham and Women’s Hospital and Massachusetts General Hospital in Boston.  Prior to joining industry, Wendy held the position of Assistant Professor in Medicine at Harvard Medical School.